Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint

(RTTNews) - Zai Lab Limited (ZLAB) and Novocure (NVCR) announced the LUNAR study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The LUNAR study is a randomized study evaluating the safety and efficacy of Tumor Treating Fields together with standard therapies for stage 4 non-small cell lung cancer following progression.

Tumor Treating Fields or TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.

Novocure plans to file a Premarket Approval application with the FDA in the second half of 2023. Novocure also plans to file for a CE Mark in the European Union concurrently with the FDA submission.

For More Such Health News, visit rttnews.com.

Shares of Novocure are up 68% in pre-market trade on Thursday.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.